- Home
- OTLK vs PLUR Comparison
OTLK vs PLUR Comparison
Compare OTLK & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- PLUR
- Stock Information
- Founded
- OTLK 2010
- PLUR 2001
- Country
- OTLK United States
- PLUR Israel
- Employees
- OTLK N/A
- PLUR N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTLK Health Care
- PLUR Health Care
- Exchange
- OTLK Nasdaq
- PLUR Nasdaq
- Market Cap
- OTLK 42.8M
- PLUR 36.9M
- IPO Year
- OTLK 2016
- PLUR N/A
- Fundamental
- Price
- OTLK $1.21
- PLUR $3.55
- Analyst Decision
- OTLK Buy
- PLUR Strong Buy
- Analyst Count
- OTLK 5
- PLUR 1
- Target Price
- OTLK $5.25
- PLUR $12.00
- AVG Volume (30 Days)
- OTLK 1.4M
- PLUR 9.2K
- Earning Date
- OTLK 08-14-2025
- PLUR 11-11-2025
- Dividend Yield
- OTLK N/A
- PLUR N/A
- EPS Growth
- OTLK N/A
- PLUR N/A
- EPS
- OTLK N/A
- PLUR N/A
- Revenue
- OTLK $1,505,322.00
- PLUR $1,336,000.00
- Revenue This Year
- OTLK N/A
- PLUR $97.38
- Revenue Next Year
- OTLK $342.80
- PLUR $293.97
- P/E Ratio
- OTLK N/A
- PLUR N/A
- Revenue Growth
- OTLK N/A
- PLUR 309.82
- 52 Week Low
- OTLK $0.79
- PLUR $3.33
- 52 Week High
- OTLK $6.98
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- OTLK 45.22
- PLUR 34.50
- Support Level
- OTLK $1.28
- PLUR $3.60
- Resistance Level
- OTLK $1.31
- PLUR $4.00
- Average True Range (ATR)
- OTLK 0.09
- PLUR 0.18
- MACD
- OTLK -0.01
- PLUR -0.03
- Stochastic Oscillator
- OTLK 0.00
- PLUR 1.24
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.